Adjuvant Chemotherapy for Resected Stage-IA Lung Adenocarcinoma With Micropapillary Histologic Pattern
Interdisciplinary CardioVascular and Thoracic Surgery · 2026
DOI: 10.1093/icvts/ivag165 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Interdisciplinary CardioVascular and Thoracic Surgery, 2026. Verfasst von Yifei Zhou und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Antineoplastic Combined Chemotherapy Protocols, Lung Neoplasms, Pneumonectomy. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shanghai Pulmonary Hospital "Elite Sail" Talent, Shanghai Pulmonary Hospital “Elite Sail” Talent.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Objectives
The micropapillary pattern (MP) is a high-risk factor for postoperative recurrence in lung adenocarcinoma (LUAD), but the role of adjuvant chemotherapy (ACT) in stage IA LUAD with MP (LUADmp) after resection remains unclear.
Methods
From September 2017 to August 2020, in the phase II trial, resected stage IA LUADmp patients received ACT (pemetrexed and carboplatin), forming the ACT-group. Patients who met the trial criteria but declining ACT during the same period were designated as the standard of care (SoC)-group. Recurrence-free survival (RFS) was compared between groups using univariate and multivariate analyses.
Results
The numbers of patients in ACT-group and SoC-group were 81 and 75, respectively. Compared to SoC-group, patients in ACT-group were younger (60.0 vs 64.0 years, P = .019), had a lower proportion of EGFR/ALK mutations (58.0% vs 78.7%, P = .006), and had a higher proportion of spread through air spaces (59.3% vs 40.0%, P = .016). At the cut-off date of January 31, 2025, the median duration of follow-up was 65.6 months. Five-year RFS in ACT-group met the prespecified primary end-point, and no significant difference was observed between ACT-group and SoC-group (ACT-group vs SoC-group: 88.9% vs 86.7%, log-rank P = .534). Multivariate analysis showed ACT could not predict RFS independently (hazards ratio [HR], 0.865, 95% CI, 0.334-2.240, P = .765).
Conclusions
Adjuvant chemotherapy was not significantly associated with improved RFS for stage IA LUADmp patients postoperatively. This study was registered at ClinicalTrials.gov: NCT03351842. Clinical registration number ClinicalTrials.gov Identifier: NCT03351842.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai 200433, China.
ORCID-Profile: Peng Zhang, Kaiqi Jin
Förderung
- National Natural Science Foundation of China
- Shanghai Pulmonary Hospital "Elite Sail" Talent
- Shanghai Pulmonary Hospital “Elite Sail” Talent
Zitieren
APA
Zhou, Y., Bian, D., Yang, F., Xu, X., Shen, Y., Chen, L., Dai, J., Xu, X., Zhu, Y., Zhao, D., Zhang, P., Liu, X., Jin, K., & Jiang, G. (2026). Adjuvant Chemotherapy for Resected Stage-IA Lung Adenocarcinoma With Micropapillary Histologic Pattern. Interdisciplinary CardioVascular and Thoracic Surgery. https://doi.org/10.1093/icvts/ivag165
Vancouver
Zhou Y, Bian D, Yang F, Xu X, Shen Y, Chen L, et al. Adjuvant Chemotherapy for Resected Stage-IA Lung Adenocarcinoma With Micropapillary Histologic Pattern. Interdisciplinary CardioVascular and Thoracic Surgery. 2026. doi:10.1093/icvts/ivag165
BibTeX
@article{Zhou2026,
author = {Zhou, Yifei and Bian, Dongliang and Yang, Fujun and Xu, Xinnan and Shen, Yingran and Chen, Linsong and Dai, Jie and Xu, Xiaoxiong and Zhu, Yuming and Zhao, Deping and Zhang, Peng and Liu, Xiaogang and Jin, Kaiqi and Jiang, Gening},
title = {Adjuvant Chemotherapy for Resected Stage-IA Lung Adenocarcinoma With Micropapillary Histologic Pattern},
journal = {Interdisciplinary CardioVascular and Thoracic Surgery},
year = {2026},
doi = {10.1093/icvts/ivag165}
}
EUVIMED